With 1health.io technology, Patients Choice Laboratories customers will be able to order tests online
The direct-to-consumer lab testing market is forecast to grow at a 22% compound annual growth from 2021 to 2031, according to research group, Transparency Marketing in its report “North America Direct-to-Consumer Laboratory Testing Market Insights, 2021-2031” published Q1 2022, hitting an $8.8 billion valuation at the end of this decade.
PCL plans to bring its proprietary PGx test, one that encompasses more than 200 medications by determining how a person’s genetic makeup metabolizes them, to the 1health platform later this year. Besides understanding how a patient’s unique body responds to common medications, which can be life-saving all on its own, there are other important benefits to PGx testing which include helping patients with chronic conditions manage their drug regimen, decreasing the need for trial-and-error dosing, and reducing overall health care costs.
“We had been looking for more than a year to find a provider to help us go-to-market directly to consumers,” states Brad Moss, President of PCL. “The direct-to-consumer market is a growing and a strategic target for us. We look forward to going live with our innovative PGx test later this year on the 1health platform,” continued Moss.
“Having Patients Choice Laboratories on the 1health platform means their customers will be able to order PCL lab tests online and intuitively- in minutes, not days or weeks. In addition, PCL customers will be able to understand the bioinformatics and reporting within the 1health platform, providing a comprehensive way to view and understand treatment recommendations quickly,” states 1health CEO Mehdi Maghsoodnia. “We are proud they have selected 1health as their go-to-market platform for their physicians, clinicians, and patients,” added Maghsoodnia.
To read the press release click HERE
To learn more about Patients Choice go to their website at Patients Choice Laboratories | Advanced Medical Laboratory Testing | Indianapolis (pclabsdx.com)
According to Straits Research, the pharmacogenomics market is $5.7 billion dollars, and is expected to grow at a CAGR of 8.47% this decade
Next generation 1health technology enables GC LabTech to quickly launch differentiated testing products to consumers
Using 1health, American Molecular Labs will deploy its proprietary tests to consumers, clinicians & partner companies
How Independent labs can grow by selling advanced screening procedures and support the US Cancer Moonshot Initiative.